Preliminary research demonstrates the biomarker’s revolutionary potential to empower accessible and scalable blood testing for Alzheimer’s disease; Quanterix to discuss latest findings and how ...

Ready to expand the possibilities of biomarker science? The Simoa® Accelerator Laboratory is a full-service center for biopharmaceutical research. The Accelerator Lab provides exploratory protein ...

Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood ...

Findings offer first-time evidence of neuro-axonal damage in mild-to-moderate cases of SARS-CoV-2 and validate serum neurofilament light chain (sNfL) as a highly specific biomarker to measure and ...

Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from ...

Quanterix specializes in ultra-sensitive digital immunoassay platforms for early disease detection, potentially transforming disease management. The company's financials show promising growth, with ...

Quanterix today plans to launch an initial public offering (IPO) of at least $64 million, with the proceeds set to be used in part toward expanding commercial operations and supporting the planned ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will expand its ...

In particular, the impact of a high-definition, blood-based Simoa assay that rivals traditional CSF or PET scans could be revolutionary, with material potential for home sampling to enable early ...